Literature DB >> 18082270

Reduced incidence of insect-bite hypersensitivity in Icelandic horses is associated with a down-regulation of interleukin-4 by interleukin-10 and transforming growth factor-beta1.

Eman Hamza1, Bettina Wagner, Thomas W Jungi, Jelena Mirkovitch, Eliane Marti.   

Abstract

Insect bite hypersensitivity (IBH) is an allergic dermatitis of horses caused by IgE-mediated reactions to bites of insects of the genus Culicoides. IBH does not occur in Iceland due to the absence of Culicoides. However, Icelandic horses exported to mainland Europe as adults (1st generation) have a > or =50% incidence of developing IBH. In contrast, their progeny (2nd generation) has a <10% incidence of IBH. Here we show that peripheral blood mononuclear cells (PBMC) from Icelandic horses born in mainland Europe and belonging either to the IBH or healthy subgroup produce less interleukin (IL)-4 after polyclonal or allergen-specific stimulation when compared with counterparts from horses born in Iceland. We examined a role of IL-10 and transforming growth factor (TGF)-beta1 in down-regulation of IL-4 in healthy 2nd generation Icelandic horses. Supernatants of PBMC from 2nd generation healthy horses down-regulated the proportion of IL-4-producing cells and IL-4 production in stimulated cultures of PBMC from 1st generation IBH. This inhibition was mimicked by a combination of IL-10 and TGF-beta1 but not by the single cytokines. Cultures of stimulated PBMC of healthy 2nd generation horses produced a low level of IL-4, but IL-4 production was increased by anti-equine IL-10 and anti-human TGF-beta1. This shows for the first time that in horses, IL-10 and TGF-beta1 combined regulate IL-4 production in vitro. It is suggested that in this naturally occurring IgE-mediated allergy, IL-10 and TGF-beta1 have a role in the down-regulation of IL-4-induced allergen-specific Th2 cells, thereby reducing the incidence of IBH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082270     DOI: 10.1016/j.vetimm.2007.10.018

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

1.  Major histocompatibility complex and other allergy-related candidate genes associated with insect bite hypersensitivity in Icelandic horses.

Authors:  Marie Klumplerova; Leona Vychodilova; Olga Bobrova; Michaela Cvanova; Jan Futas; Eva Janova; Mirko Vyskocil; Irena Vrtkova; Lenka Putnova; Ladislav Dusek; Eliane Marti; Petr Horin
Journal:  Mol Biol Rep       Date:  2012-12-30       Impact factor: 2.316

2.  Equine CD4(+) CD25(high) T cells exhibit regulatory activity by close contact and cytokine-dependent mechanisms in vitro.

Authors:  Eman Hamza; Vinzenz Gerber; Falko Steinbach; Eliane Marti
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

3.  Impaired Cell Cycle Regulation in a Natural Equine Model of Asthma.

Authors:  Alicja Pacholewska; Vidhya Jagannathan; Michaela Drögemüller; Jolanta Klukowska-Rötzler; Simone Lanz; Eman Hamza; Emmanouil T Dermitzakis; Eliane Marti; Tosso Leeb; Vincent Gerber
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

4.  Phenotype and function of IgE-binding monocytes in equine Culicoides hypersensitivity.

Authors:  Elisabeth M Larson; Susanna Babasyan; Bettina Wagner
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

5.  Allergen-specific immunoglobulin E in sera of horses affected with insect bite hypersensitivity, severe equine asthma or both conditions.

Authors:  Maëva Verdon; Simone Lanz; Claudio Rhyner; Vinzenz Gerber; Eliane Marti
Journal:  J Vet Intern Med       Date:  2018-12-06       Impact factor: 3.333

6.  First clinical expression of equine insect bite hypersensitivity is associated with co-sensitization to multiple Culicoides allergens.

Authors:  Jasmin Birras; Samuel J White; Sigridur Jonsdottir; Ella N Novotny; Anja Ziegler; A Douglas Wilson; Rebecka Frey; Sigurbjörg Torsteinsdottir; Marcos Alcocer; Eliane Marti
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.